Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings

Abdominal Imaging

Volumn 38, Issue 3, 2013, Pages 552-560

  Naswa, Niraj ^a   Sharma, Punit ^a   Soundararajan, Ramya ^a   Karunanithi, Sellam ^a   Nazar, Aftab Hasan ^a   Kumar, Rakesh ^a   Malhotra, Arun ^a   Bal, Chandrasekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

68Ga DOTANOC; Contrast enhanced CT; Gastrinoma; PET CT

Indexed keywords

[1,4,7,10 TETRAAZACYCLO DODECANE 1,4,7,10 TETRAACETIC ACID] 1 NAL 3 OCTREOTIDE GA 68; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 68GA-DOTANOC; GALLIUM; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DUODENUM; ENDOSCOPY; FEMALE; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; PET SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH; TUMOR LOCALIZATION; DIAGNOSTIC USE; IMAGE PROCESSING; MIDDLE AGED; MULTIMODAL IMAGING; PANCREAS TUMOR; RADIOGRAPHY; SCINTISCANNING;

ADULT; FEMALE; GALLIUM RADIOISOTOPES; GASTRINOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN;

EID: 84879094579     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-012-9925-z     Document Type: Article

References (28)

1. Wise SR, Johnson J, Sparks J, et al. (1989) Gastrinoma: the value of preoperative localization. Surgery 106:1087-1093
2. Frucht H, Doppman JL, Norton JA, et al. (1989) MR imaging of gastrinomas: comparison with computed tomography, angiography and ultrasound. Radiology 171:713-717
3. Imamura M, Takahasi K, Adachi H, et al. (1987) Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 205:230-239
4. Rosch T, Lightdale CJ, Botet JF (1992) Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326:1721-1726
5. Kvols LK (1993) Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. Gastroenterology 105:1909-1914
6. de Kerviler E, Cadiot G, Lebtahi R, et al. (1994) Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: groupe d'Etude du syndrome de Zollinger-Ellison. Eur J Nucl Med 21:1191-1197
7. Gibril F, Reynolds JC, Doppman JL, et al. (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26-34
8. Antunes P, Ginj M, Zhang H, et al. (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982-993
9. Buchmann I, Henze M, Engelbrecht S, et al. (2007) Comparison of 68 Ga-DOTATOC PET and 111In-DTPAOC (octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617-1626
10. 68Ga-DOTA-D Phe(1)-Tyr(3)- Octreotide in comparison to 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42-48
11. 68Ga-DOTA- Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518
12. Naswa N, Sharma P, Kumar A, et al. (2011) Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 197:1221-1228
13. Kumar R, Sharma P, Garg P, et al. (2011) Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408-2416
14. Versari A, Camellini L, Carlinfante G, et al. (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 35:321-328
15. 68Ga for medical application. J Nucl Med 48:1741-1748
16. 68Ga-DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669-673
17. 68Ga DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med 37:245-251
18. Norton JA, Doppman JL, Jensen RT (1992) Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 215:8-18
19. Fraker DL, Norton JA, Alexander HR, et al. (1994) Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220:320-330
20. Stabile BE, Passaro E Jr (1985) Benign and malignant gastrinoma. Am J Surg 49:144-150
21. Weber HC, Venzon DJ, Lin JT, et al. (1995) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637-1649
22. Ellison EH, Wilson SD (1964) The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 160:512-530
23. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 50:1214-1221
24. Jensen RT (1996) Gastrinoma. Bailliere's Clin Gastroenterol 10:603-643
25. Banasch M, Schmitz F (2007) Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 119:573-578
26. Jais P, Mignon M (1995) Normal serum gastrin concentration in gastrinoma. Lancet 346:1421-1422
27. Yanda RJ, Ostroff JW, Ashbaugh CD, et al. (1989) Zollinger-Ellison syndrome in a patient with normal screening gastrin level. Dig Dis Sci 34:1929-1932
28. Wolfe MM, Jain DK, Edgerton JR (1985) Zollinger-Ellison syndrome associated with persistently normal fasting serum gastrin concentrations. Ann Intern Med 103:215-217